Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Carfilzomib - Onyx Pharmaceuticals

Next Previous
X
Search
Drug Profile

Carfilzomib - Onyx Pharmaceuticals

Alternative Names: Kyprolis; ONO-7057; PR-171

Latest Information Update: 30 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Proteolix
  • Developer AbbVie; Amgen; Dana-Farber Cancer Institute; Genentech; GSK; Janssen Biotech; M. D. Anderson Cancer Center; Ohio State University Comprehensive Cancer Center; Ono Pharmaceutical; Onyx Pharmaceuticals; Phoenix Children's Hospital; Roswell Park Cancer Institute; The Innovative Therapies for Children with Cancer; Therapeutic Advances in Childhood Leukemia & Lymphoma; University of Alabama at Birmingham; University of Birmingham; University of California at San Francisco; University of California, Davis; University of Rochester; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Epoxy compounds; Oligopeptides; Small molecules
  • Mechanism of Action Proteasome inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma; Precursor cell lymphoblastic leukaemia-lymphoma; Waldenstrom's macroglobulinaemia
  • New Molecular Entity Yes
  • Available For Licensing Yes - Multiple myeloma

Highest Development Phases

  • Marketed Multiple myeloma
  • Phase III Waldenstrom's macroglobulinaemia
  • Phase II Mantle-cell lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Prostate cancer; Renal cell carcinoma
  • Phase I/II Diffuse large B cell lymphoma; Peripheral T-cell lymphoma; Small cell lung cancer; Solid tumours
  • No development reported Leukaemia; Lymphoid leukaemia; Lymphoma; Non-Hodgkin's lymphoma; Systemic lupus erythematosus

Most Recent Events

  • 28 Jun 2024 Onyx Pharmaceuticals completes the phase I/II trials in Precursor cell lymphoblastic leukaemia-lymphoma (Combination therapy, Monotherapy, In adolescents, In adults, In children, In infants, Second-line therapy or greater) in Turkey, Taiwan, Sweden, South Korea, Singapore, Russia, Romania, Portugal, Portugal, Poland, Hong Kong, Greece, Greece, Brazil, Bulgaria, Argentina, Thailand, South Africa, Saudi Arabia, Norway, Mexico, Czech Republic, Colombia, Chile (IV) (NCT02303821) (EudraCT2014-001633-84)
  • 12 Apr 2024 Amgen and Arbeitsgemeinschaft medikamentoese Tumortherapie completes a phase II trial in Multiple myeloma (Combination therapy, First line therapy) in Austria and Germany (NCT02891811) (EudraCT2016-000475-24)
  • 07 Nov 2023 Stanford University and Amgen completes a phase-I trial in Solid Tumours and Leukaemia (In infants, children, Adolescents, In adults, Second-line therapy or greater)in Canada and USA (NCT02512926)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top